IMV Рыночная капитализация

Что обозначает Рыночная капитализация в IMV?

Рыночная капитализация IMV, Inc. является $18.53M

Какое определение для Рыночная капитализация?



Рыночная капитализация - это рыночная стоимость в тот момент времени, когда акции, находящиеся в обращении публичной компании, равна цене акций в тот отрезок времени, умноженной на количество акций в обращении .

As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.

Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.

The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.

Рыночная капитализация компаний в Health Care сектор на TSX по сравнению с IMV

Что делает IMV?

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Компании с рыночная капитализация похож на IMV



  • Pulse Oil имеет Рыночная капитализация из $18.50M
  • Akme Star Housing Finance имеет Рыночная капитализация из $18.50M
  • Namaste Technologies имеет Рыночная капитализация из $18.50M
  • Ying Hai имеет Рыночная капитализация из $18.50M
  • UrbanGold Minerals имеет Рыночная капитализация из $18.51M
  • Subversive Capital Acquisition имеет Рыночная капитализация из $18.52M
  • IMV имеет Рыночная капитализация из $18.53M
  • Black Iron имеет Рыночная капитализация из $18.53M
  • Clever Leaves имеет Рыночная капитализация из $18.54M
  • Fe имеет Рыночная капитализация из $18.54M
  • Optimumbank имеет Рыночная капитализация из $18.54M
  • IL&FS Transportation Networks имеет Рыночная капитализация из $18.55M
  • Shield Therapeutics Plc имеет Рыночная капитализация из $18.55M